Osteonecrosis and Bisphosphonates in Oral and Maxillofacial Surgery

Oral and Maxillofacial Surgery Clinics of North America

Volumn 19, Issue 2, 2007, Pages 199-206

  Chaudhry, Ahmad N ^a   Ruggiero, Salvatore L ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; HUMAN; JAW DISEASE; ORAL SURGERY; QUALITY OF LIFE; REVIEW;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; QUALITY OF LIFE;

EID: 34248656982     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coms.2007.01.005     Document Type: Review

References (80)

1. Marx RE, Stern D. Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Carol Stream (IL): Quintessence; 2003. p. 36-8.
2. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104-1107
3. Mehrotra B., Fantasia J., Nissel-Horowitz S., et al. Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. A case report. [abstract 3194]. Proceedings of the American Society of Clinical Oncology 22 (2003) 795
4. Rosenberg T.J., and Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. [abstract]. J Oral Maxillofac Surg 61 Suppl 1 (2003) 60
5. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. [letter]. J Oral Maxillofac Surg 61 (2003) 1115-1117
6. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. [letter]. J Clin Oncol 21 (2003) 4253-4254
7. Carter G., and Goss A. Bisphosphonates and avascular necrosis of the jaws. [letter]. Aust Dent J 48 (2003) 268-269
8. Estillo C.L., Williams T., Evtimovska E., et al. Osteonecrosis of the maxilla and mandible: possible drug-induced complication of bisphosphonate therapy. [abstract]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 (2004) 449
9. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
10. Schwartz H.C. Osteonecrosis and bisphosphonates: correlation versus causation. [letter]. J Oral Maxillofac Surg 62 (2004) 763-764
11. Ruggiero S.L., and Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. [correspondence, author reply]. N Engl J Med 351 (2004) 191
12. Robinson N.A., and Yeo J.F. Bisphosphonates: a word of caution. Ann Acad Med Singap 33 4 Suppl (2004) 48-49
13. Ruggiero S., Woo V., Mehrotra B., et al. Osteonecrosis of the jaws associated with the use of bisphosphonate medications: a report of 60 cases. [abstract]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 (2004) 196-197
14. Lugassy G., Shaham R., Nemets A., et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Hematol 117 (2004) 440-441
15. Greenberg M.S. Intravenous bisphosphonates and osteonecrosis. [editorial]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2004) 259-260
16. Durie B.G.M., Katz M., McCoy J., et al. Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia and Zometa use. [abstract]. Blood 104 11 (2004) 99-100
17. Altundag K., Altundag O., and Gundeslioglu O. Multiple myeloma. [letter]. N Engl J Med 352 (2005) 840
18. Kyle R.A., and Rajkumar S.V. Multiple myeloma. [author's reply]. N Engl J Med 352 (2005) 841-842
19. Melo M.D., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 (2005) 111-113
20. Bagan J.V., Murillo J., Jimenez Y., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34 (2005) 120-123
21. Migliorati C.A. Bisphosphonate-associated oral osteonecrosis. [letter]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 (2005) 135-140
22. Vannucchi A.M., Ficarra G., Antonioli E., et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Hematol 128 (2005) 738-740
23. Carter G., Goss A.N., and Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 182 (2005) 413-415
24. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw: Adverse Drug Reactions Advisory Report. Med J Aust 182 (2005) 417-418
25. Abramowicz M, editor. Alendronate (Fosamax) and risedronate (Actonel) revisited. Med Lett Drugs Ther 2005;47(1207):33-35.
26. Hasegawa Jr. T.K., Matthews M., and Grogan D. Ethical dilemma #51: Dealing with uncertainty: bisphosphonate-related osteonecrosis. Tex Dent J 122 (2005) 385-387
27. Philipone E. Nonhealing extraction site. Gen Dent 53 (2005) 163-165
28. Hellstein J.W., and Marek C.L. Bisphosphonate osteonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682-689
29. Guarino M.J., Hill C.E., and Patel K. Bisphosphonates, cancer and osteonecrosis: a single practice experience. Del Med J 77 (2005) 181-187
30. Hellstein J.W. Osteonecrosis warning: cancer drugs preclude some dental procedures. American Dental Association News, May 16, (2005) 12
31. Nelson M.V.B. Special precautions. [letter]. Br Dent J 198 (2005) 628
32. Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. Can Med Assoc J 172 (2005) 1684-1686
33. Ruggiero S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates. Bulletin of the Nassau County Dental Society 10 (2005) 31-35
34. Johnson T., Holder R., and Johnson B. Bisphosphonate-related osteonecrosis of the jaws. [letter]. Spec Care Dentist 21 3 (2005) 4-7
35. Migliorati C.A., Schubert M.M., Petersen D.E., et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
36. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. [letter]. N Engl J Med 353 (2005) 99-100
37. Woo S.B., Hande K., and Richardson P.G. Osteonecrosis of the jaw and bisphosphonates. [letter]. N Engl J Med 353 (2005) 100
38. Maerevoet M., Martin C., and Duck L. Osteonecrosis of the jaw and bisphosphonates. [letter]. N Engl J Med 353 (2005) 100-101
39. Tarassoff P., and Hei Y. Osteonecrosis of the jaw and bisphosphonates. [reply]. N Engl J Med 353 (2005) 101-102
40. Jimenez-Soriano Y., and Bagan J.V. Bisphosphonates as a new cause of drug-induced jaw osteonecrosis: an update. [letter]. Med Oral Patol Oral Cir Bucal 10 Suppl 2 (2005) E88-E91
41. Schrimer I., Peters H., Reichart P.A., et al. Bisphosphonates and osteonecrosis of the jaw. Mund Kiefer Gesichtschir 9 (2005) 239-245
42. Sanna G., Zampino M.G., Pelosi G., et al. Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 16 (2005) 1207-1208
43. Donoghue A.M. Bisphosphonates and osteonecrosis: analogy to phossy jaw. [letter]. Med J Aust 183 (2005) 163-164
44. Olson K.B., Hellie C.M., and Pienta K.J. Osteonecrosis of the jaw in a patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 66 (2005) 658-660
45. Steiner B., Lenz J.H., Gundlach K.K., et al. Osteonecrosis of the jaws during treatment with bisphosphonates: diagnosis and therapeutic options. Dtsch Med Wochenschr 130 (2005) 2142-2145
46. Sarathy A.P., Bourgeois S.L., and Goodell G.G. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31 (2005) 759-763
47. Mehrotra B., and Ruggiero S.L. Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update. Blood 106 (2005) Abstract #291
48. Watts N. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 19 (2003) 395-414
49. Berensen J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736
50. Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 (1995) 1478-1487
51. Murakami H., Takahashi N., Sasaki T., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17 (1995) 137-144
52. Hughes D.E., MacDonald B.R., Russell R.G.G., et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83 (1989) 1930-1935
53. Kapitola J., Zak J., Lacinova Z., et al. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 49 Suppl 1 (2000) S101-S106
54. Kapitola J., and Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res 47 (1998) 237-240
55. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538-6544
56. Corso A., Ferretti E., Lunghi M., et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104 (2005) 118-125
57. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
58. Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General (2004), Department of Health and Human Services, Rockville (MD)
59. Gabriel S.E., Tosteson A.N., Leibson C.L., et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13 (2002) 323-330
60. Rosen C. Postmenopausal osteoporosis. N Engl J Med 353 6 (2005) 595-603
61. Black D.M., Cummings S.R., Karpf D.B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
62. Hosking D., Chilvers C.E.D., Christiansen C., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: early postmenopausal intervention cohort study group. N Engl J Med 338 (1998) 485-492
63. Ravn P., Bidstrup M., Wasnick R.D., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study randomized, controlled trial. Ann Intern Med 131 (1999) 935-942
64. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
65. Miller P., Roux C., McClung M., et al. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. [abstract]. Arthritis Rheum 42 Suppl 9 (1999) S287
66. Ferlay J., Bray F., Pisani P., et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5 (2001), IARCPress, Lyon (France)
67. RE Coleman. Metastatic bone disease clinical features, pathophysiology and treatment strategies, Cancer Treat Rev 27 (2001), 165-176.
68. Coleman R.E. Skeletal complications of malignancy. Cancer 80 Suppl (1997) 1588-1594
69. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
70. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
71. Van Beek E.R., Lowick C.W., and Papapulos S.E. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylation in the action of nitrogen-containing bisphosphonates or osteoclast precursors. Bone 30 (2002) 64-69
72. Rogers MJ, Gordon S, HL Benfored, et al. Cellular and molecular mechanisms of action of bisphosphonates: skeletal complications of malignancy. Cancer 2000;Suppl 88:2961-3.
73. Marx R, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75.
74. Dimopoulos M., Kastritis E., Moulopoulos L.A., et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood 106 (2005) [abstract #637]
75. Tosi P., Zamagni E., Cangini D., et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid. Blood 106 (2005) [abstract #3461]
76. Pozzi S., Marcheselli R., Sacchi S., et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood 106 (2005) [abstract #5057]
77. Gallucci C., Agrillo A., Iannetti G., et al. Possible role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients. Blood 106 (2005) [abstract # 3460]
78. Cafro A.M., Barbarano L.A., Andriani A., et al. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience. Blood 106 (2005) [abstract #5152]
79. Badros A., Weikel D., Salama A., et al. Ostonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
80. American Dental Association. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. Report of the Council on Scientific Affairs. Chicago (IL): American Dental Association. June, 2006.